This new class of diagnostic testing — liquid biopsy — is enabling our understanding of the genomic landscape and functionality of cancer as well as developing enhanced precision medicine approaches to patient treatment and management.

PlasmaDx: A Class Apart

Because tumors release their DNA and tumor cells (primary or metastatic) into the bloodstream, sensitive techniques have been developed to detect these distinct signatures (biomarkers), yielding actionable diagnostic information. The two types of biomarkers are most often interrogated through liquid biopsy are:

  • Circulating tumor DNA (ctDNA), a component of cell-free DNA (cfDNA)
  • Circulating tumor cells (CTCs)

Of the two types, ctDNA is more accessible in plasma. Levels of ctDNA have been found to correlate with tumor burden, treatment response, relapse or surgery and to indicate disease proliferation. With the development of sensitive techniques enabling detection of rare mutations and genetic alterations (SNVs, CNVs, fusions, indels), liquid biopsy makes it possible to understand the heterogeneous landscape of the tumor and identify therapeutic targets for treatment planning purposes.

 

PlasmaDx Monitoring

PlasmaDx Monitoring is a collection of ctDNA tests from the AVENIO ctDNA Assay Portfolio (Roche Sequencing Systems) validated for use in our PacificDx CAP/CLIA laboratory. PlasmaDx Monitoring covers a variety of clinical oncology research scenarios and provides support for biopharmaceutical clinical trials.

TEST FEATURES

  • 5 day turn-around-time (TAT)
  • High (> 90 percent sensitivity) at low ≥ 0.5 percent allele frequencies
  • Broad coverage across tumor types

CLINICAL FEATURES

Each assay provides information about the status of clinically-actionable genomic alterations (SNVs, indels, fusions, CNAs) including those targeted by FDA-approved therapeutics. A matched tissue/plasma testing option is also available.

Our PLASMADx Monitoring Options:

  • Analyzes hotspot areas of 17 cancer-related genes
  • Optimized for non-small cell lung cancer (NSCLC) and colorectal cancer (CRC)
  • Applicable for pan-cancer applications
  • Best choice for on-label therapeutic decision-making or plasma monitoring of tumors with known EGFR, KRAS, BRAF genomic alterations
  • Analyzes hotspot areas of 77 cancer-related genes
  • Optimized for NSCLC and CRC with expanded gene list and hotspot coverage
  • Applicable for plasma monitoring of tumor burden and identification of targetable genomic alterations
  • Best choice for higher coverage for pan-cancer applications and biomarker discovery
  • Analyzes hotspot and whole exon targets of 197 cancer-related genes
  • Includes guideline driven and emerging tumor biomarkers for therapeutic decision making
  • Applicable for longitudinal monitoring of tumor burden and identification of targetable genomic alterations.
  • Best choice for detecting a patient’s cancer personalized profile by deep sequencing (CAPP-Seq)
  • Analyzes matched tissue DNA and ctDNA from plasma simultaneously using PlasmaDX’s Targeted, Expanded, or Surveillance tests at the time of diagnosis, recurrence, and metastases
  • Applicable for small high grade tumors at the time of diagnosis and pre/post-surgery tumor burden monitoring
  • Best choice for biomarker identification in tissue followed by monitoring in plasma ctDNA